PMID- 29146887
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 2049-3614 (Print)
IS  - 2049-3614 (Electronic)
IS  - 2049-3614 (Linking)
VI  - 7
IP  - 1
DP  - 2018 Jan
TI  - Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical 
      strategies and future targets.
PG  - R1-R25
LID - 10.1530/EC-17-0286 [doi]
AB  - Molecular targeted therapy of advanced neuroendocrine tumours (NETs) of the 
      gastroenteropancreatic (GEP) system currently encompasses approved therapy with 
      the mammalian target of rapamycin (mTOR) inhibitor everolimus and the 
      multi-tyrosinkinase inhibitor sunitinib. However, clinical efficacy of these 
      treatment strategies is limited by low objective response rates and limited 
      progression-free survival due to tumour resistance. Further novel strategies for 
      molecular targeted therapy of NETs of the GEP system are needed. This paper 
      reviews preclinical research models and signalling pathways in NETs of the GEP 
      system. Preclinical and early clinical data on putative novel targets for 
      molecular targeted therapy of NETs of the GEP system are discussed, including 
      PI3K, Akt, mTORC1/mTORC2, GSK3, c-Met, Ras-Raf-MEK-ERK, embryogenic pathways 
      (Hedgehog, Notch, Wnt/beta-catenin, TGF-beta signalling and SMAD proteins), 
      tumour suppressors and cell cycle regulators (p53, cyclin-dependent kinases 
      (CDKs) CDK4/6, CDK inhibitor p27, retinoblastoma protein (Rb)), heat shock 
      protein HSP90, Aurora kinase, Src kinase family, focal adhesion kinase and 
      epigenetic modulation by histone deacetylase inhibitors.
CI  - (c) 2018 The authors.
FAU - Aristizabal Prada, E T
AU  - Aristizabal Prada ET
AD  - Department of Internal Medicine IVCampus Grosshadern, University-Hospital, 
      Ludwig-Maximilians-University of Munich, Munich, Germany.
FAU - Auernhammer, C J
AU  - Auernhammer CJ
AD  - Department of Internal Medicine IVCampus Grosshadern, University-Hospital, 
      Ludwig-Maximilians-University of Munich, Munich, Germany 
      christoph.auernhammer@med.uni-muenchen.de.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171116
PL  - England
TA  - Endocr Connect
JT  - Endocrine connections
JID - 101598413
PMC - PMC5754510
OTO - NOTNLM
OT  - neuroendocrine tumours
OT  - targeted therapy
EDAT- 2017/11/18 06:00
MHDA- 2017/11/18 06:01
PMCR- 2017/11/16
CRDT- 2017/11/18 06:00
PHST- 2017/10/02 00:00 [received]
PHST- 2017/11/16 00:00 [accepted]
PHST- 2017/11/18 06:00 [pubmed]
PHST- 2017/11/18 06:01 [medline]
PHST- 2017/11/18 06:00 [entrez]
PHST- 2017/11/16 00:00 [pmc-release]
AID - EC-17-0286 [pii]
AID - EC170286 [pii]
AID - 10.1530/EC-17-0286 [doi]
PST - ppublish
SO  - Endocr Connect. 2018 Jan;7(1):R1-R25. doi: 10.1530/EC-17-0286. Epub 2017 Nov 16.